Jul 27, 2026 06:09AM
Jul 24, 2026 02:40PM
Jul 24, 2026 02:40PM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:02AM
Jun 1, 2026 08:47AM
Jun 1, 2026 08:46AM Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 28, 2026 04:00PM
May 28, 2026 04:00PM
May 26, 2026 07:03AM
May 26, 2026 07:00AM
May 18, 2026 06:08AM
May 15, 2026 04:05PM
Apr 23, 2026 04:05PM Outlook Therapeutics completes $5 million stock offering
Apr 23, 2026 04:05PM
Apr 22, 2026 08:30AM
Apr 22, 2026 08:30AM
Apr 21, 2026 09:05AM
Apr 21, 2026 09:05AM
Apr 7, 2026 08:56AM
Apr 7, 2026 08:50AM Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Apr 7, 2026 08:50AM
Mar 25, 2026 04:05PM
Mar 25, 2026 04:05PM
Mar 24, 2026 07:00AM
Mar 24, 2026 07:00AM
Mar 23, 2026 05:30PM
Mar 23, 2026 05:30PM Outlook Therapeutics Announces Proposed Public Offering
Mar 16, 2026 08:06AM
Mar 16, 2026 08:05AM
Mar 5, 2026 04:16PM
Mar 5, 2026 04:15PM
Feb 17, 2026 08:05AM
Feb 11, 2026 08:45AM
Feb 11, 2026 08:45AM Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Jan 5, 2026 06:41AM
Jan 2, 2026 07:02AM
Dec 31, 2025 04:15PM
Dec 31, 2025 04:15PM
Dec 19, 2025 08:05AM
Dec 19, 2025 08:05AM
Nov 13, 2025 08:31AM Outlook Therapeutics gets FDA acceptance for wet AMD drug application
Nov 13, 2025 08:30AM
Nov 3, 2025 08:35AM
Nov 3, 2025 08:35AM
Sep 30, 2025 06:54AM
Sep 29, 2025 04:03PM
Sep 29, 2025 08:45AM
Sep 29, 2025 08:45AM Outlook Therapeutics Provides Update on Type A Meeting with FDA
Sep 2, 2025 08:35AM

326,565 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All